Inozyme up as co on track to report early-stage data for rare disease therapy

Inozyme Pharma

14/04/2023 19:33

** Shares of rare disease therapy developer Inozyme Pharma
INZY.O up about 4.4% at $5.8
    ** Says on track to report interim data from early stage
trials of its drug to treat rare genetic disorders called ENPP1
and ABCC6 deficiencies in Q3 2023
    ** Plans to add an additional cohort to investigate the
potential for once-weekly dosing in the ongoing trial
    ** Co had earlier reported that patients treated with the
drug showed significant increases in levels of plasma
pyrophosphate in the blood of patients with the disorders, which
is essential for preventing the build up of calcium in soft
tissues
    ** INZY up about 448% YTD

 (Reporting by Vaibhav  Sadhamta)
 ((Vaibhav.Sadhamta@thomsonreuters.com;))